Leivers, Martin; Miller, John F.; Chan, Stephanie A.; Lauchli, Ryan; Liehr, Sebastian; Mo, Wenyan; Ton, Tony; Turner, Elizabeth M.; Youngman, Michael; Falls, J. Greg; Long, Susan; Mathis, Amanda; Walker, Jill published the artcile< Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure-Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism>, Safety of 3-Chloro-6-(chloromethyl)pyridazine, the main research area is imidazopyridazine hepatitis C antiviral polymerase structure activity preparation.
By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodrug mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.
Journal of Medicinal Chemistry published new progress about Antiviral agents. 120276-59-7 belongs to class pyridazine, and the molecular formula is C5H4Cl2N2, Safety of 3-Chloro-6-(chloromethyl)pyridazine.
Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem